Showing results (1261-1270 of 1,302) with videos related to
Sort By:
Pageof 131
Bioorganic & Medicinal Chemistry Letters|August 21, 2012
Novel triazines as potent and selective phosphodiesterase 10A inhibitorsMichael S Malamas, Hans Stange, Rudolf Schindler, et al.Journal of Neuro-Oncology|May 6, 2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 studyLinda Dirven, Ralf Luerding, Dagmar Beier, et al.Nature Medicine|September 22, 2023
A H3K27M-targeted vaccine in adults with diffuse midline gliomaNiklas Grassl, Isabel Poschke, Katharina Lindner, et al.Proceedings of the National Academy of Sciences of the United States of America|April 21, 2010
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypesMichele P Kelly, Sheree F Logue, Julie Brennan, et al.Stroke|May 15, 2020
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired SubgroupsHans-Christoph Diener, Ralph L Sacco, J Donald Easton, et al.Neuro-Oncology Advances|October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastomaLazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activitiesFeng Liu, Steve Grauer, Cody Kelley, et al.Cancer Medicine|April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging AnalysisLazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.Nature Communications|February 9, 2024
T-bet+ B cells are activated by and control endogenous retroviruses through TLR-dependent mechanismsEileen Rauch, Timm Amendt, Aleksandra Lopez Krol, et al.Lancet (London, England)|July 31, 2017
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialBente L Langdahl, Cesar Libanati, Daria B Crittenden, et al.Pageof 131